Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 18;6(14):4147–4156. doi: 10.1182/bloodadvances.2021006303

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

PMC Copyright notice

Figure 3. — OS after allogeneic HSCT. The effect of HSCT on OS was explored by excluding the effect of follow-up salvage therapy. (A) In patients in the TP53WT ITT population who advanced to HSCT, OS was numerically worse in the idasa-C group than in the placebo-C group, and those who did not receive HSCT had worse OS. (B) In patients in the TP53WT ITT population, excluding those who received follow-up salvage therapies, survival was similar between treatment groups in both those who received HSCT and those who did not.